Top

Published in:

01-10-2008 | Case Report

Hyperimmunoglobulinemia D and periodic fever syndrome; treatment with etanercept and follow-up

Authors: Rezan Topaloğlu, Nuray Aktay Ayaz, Hans R. Waterham, Aysel Yüce, Fatma Gumruk, Özden Sanal

Published in: Clinical Rheumatology | Issue 10/2008

Abstract

The hyperimmunoglobulinemia D and periodic fever syndrome (HIDS) is an autoinflammatory syndrome. It is caused by the mutations of the mevalonate kinase gene. There is no consensus for specific therapy of HIDS, but there are some case reports and studies in regards to its treatment with drugs like colchicine, steroids, nonsteroid anti-inflammatory drugs, simvastatin, anakinra, thalidomide, and etanercept. We are reporting a case evaluated for the complaints of abdominal pain and febrile episodes with massive hepatomegaly, not common finding on physical examination, its treatment with etanercept, and long-term follow-up.

Drenth JP, Cuisset L, Grateau G et al (1999) Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat Genet 22:178–181PubMedCrossRef

Drenth JP, Denecker NE, Prieur AM et al (1995) Hyperimmunoglobulin D syndrome. Presse Med 24:1211–1213PubMed

Drenth JP, Haagsma CJ, van der Meer JM (1994) Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimore) 73:133–144

de Dios Garcia D, varez-Blanco MJ (2001) Glucocorticoids but not NSAID abort attacks in hyper-IgD and periodic fever syndrome. J Rheumatol 28:925–926

Simon A, Drewe E, van der Meer JW et al (2004) Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 75:476–483PubMedCrossRef

Drenth JP, Vonk AG, Simon A et al (2001) Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever: a randomized, double-blind, placebo-controlled trial. J Pharmacol Exp Ther 298(3):1221–1226PubMed

Bodar EJ, van der Hilst JC, Drenth JP et al (2005) Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med 63(7):260–264PubMed

Drenth JP, van Deuren M, van der Ven-Jongekrijg J et al (1995) Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Blood 85(12):3586–3593PubMed

Arkwright PD, McDermott MF, Houten SM et al (2002) Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept. Clin Exp Immunol 130(3):484–488PubMedCrossRef

10.

Demirkaya E, Çağlar MK, Waterham HR et al (2007) A patient with hyper-IgD syndrome responding to anti-TNF treatment. Clin Rheumatol 26:1757–1759PubMedCrossRef

11.

Topaloğlu R, Saatçi Ü (1991) Hyperimmunoglobulinemia D and periodic fever mimicking familial Mediterranean fever in the Mediterranean. Postgrad Med J 67(787):490–491PubMedCrossRef

12.

Çoban E, Terzioğlu E (2004) A patient with hyper-IgD syndrome in Antalya, Turkey. Clin Rheumatol 23:177–178PubMedCrossRef

13.

Mandey SHL, Schneiders MS, Koster J et al (2006) Mutational spectrum and genotype phenotype correlations in mevalonate kinase deficiency. Hum Mutat 27(8):796–802PubMedCrossRef

14.

Rabinovich E, Livneh A, Langevitz P et al (2005) Severe disease in patients with rheumatoid arthritis carrying a mutation in the Mediterranean fever gene. Ann Rheum Dis 64(7):1009–1014PubMedCrossRef

15.

Hinson DD, Rogers ZR, Hoffmann GF et al (1998) Hematological abnormalities and cholestatic liver disease in two patients with mevalonate kinase deficiency. Am J Med Genet 88:408–412CrossRef

Title: Hyperimmunoglobulinemia D and periodic fever syndrome; treatment with etanercept and follow-up
Authors: Rezan Topaloğlu
Nuray Aktay Ayaz
Hans R. Waterham
Aysel Yüce
Fatma Gumruk
Özden Sanal
Publication date: 01-10-2008
Publisher: Springer-Verlag
Published in: Clinical Rheumatology / Issue 10/2008
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-008-0911-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2008

Ibandronate: is there an effect on nonvertebral fractures?

Rare association of antisynthetase syndrome and Kennedy’s disease

The autonomic dysfunction in patients with ankylosing spondylitis: a clinical and electrophysiological study

Etanercept increases adiponectin level in woman with rheumatoid arthritis

The place of methotrexate perioperatively in elective orthopedic surgeries in patients with rheumatoid arthritis

Lipstick consumption and systemic lupus erythematosus: nothing to gloss over

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials